342 related articles for article (PubMed ID: 20460347)
1. In vivo neutralization of unfractionated heparin and low-molecular-weight heparin by a novel salicylamide derivative.
Kuziej J; Litinas E; Hoppensteadt DA; Liu D; Walenga JM; Fareed J; Jeske W
Clin Appl Thromb Hemost; 2010 Aug; 16(4):377-86. PubMed ID: 20460347
[TBL] [Abstract][Full Text] [Related]
2. Relative neutralization of the biological actions of sulfaminoheparosans (K5 derivatives) and heparins by protamine sulfate.
Maddineni J; Hoppensteadt DA; Cornelli U; Manoni M; Fareed J
Clin Appl Thromb Hemost; 2007 Jan; 13(1):52-64. PubMed ID: 17164496
[TBL] [Abstract][Full Text] [Related]
3. Neutralization of enoxaparine-induced bleeding by protamine sulfate.
Van Ryn-McKenna J; Cai L; Ofosu FA; Hirsh J; Buchanan MR
Thromb Haemost; 1990 Apr; 63(2):271-4. PubMed ID: 2163553
[TBL] [Abstract][Full Text] [Related]
4. Neutralization of a low molecular weight heparin (LHN-1) and conventional heparin by protamine sulfate in rats.
Diness V; Ostergaard PB
Thromb Haemost; 1986 Dec; 56(3):318-22. PubMed ID: 3563964
[TBL] [Abstract][Full Text] [Related]
5. Antagonism of SR 90107A/Org 31540-induced bleeding by protamine sulfate in rats and mice.
Bernat A; Hoffmann P; Herbert JM
Thromb Haemost; 1996 Nov; 76(5):715-9. PubMed ID: 8950779
[TBL] [Abstract][Full Text] [Related]
6. Low molecular weight heparin and haemodialysis: neutralization by protaminchloride.
Andrassy K
Blood Coagul Fibrinolysis; 1993 Dec; 4 Suppl 1():S39-43. PubMed ID: 8180328
[TBL] [Abstract][Full Text] [Related]
7. Protamine neutralisation of low molecular weight heparins and their oligosaccharide components.
Schroeder M; Hogwood J; Gray E; Mulloy B; Hackett AM; Johansen KB
Anal Bioanal Chem; 2011 Jan; 399(2):763-71. PubMed ID: 20922518
[TBL] [Abstract][Full Text] [Related]
8. Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Hirsh J; Raschke R
Chest; 2004 Sep; 126(3 Suppl):188S-203S. PubMed ID: 15383472
[TBL] [Abstract][Full Text] [Related]
9. Studies on the neutralizing effects of protamine on unfractionated and low molecular weight heparin (Fragmin) at the site of activation of the coagulation system in man.
Wolzt M; Weltermann A; Nieszpaur-Los M; Schneider B; Fassolt A; Lechner K; Eichler HG; Kyrle PA
Thromb Haemost; 1995 Mar; 73(3):439-43. PubMed ID: 7667826
[TBL] [Abstract][Full Text] [Related]
10. Differential Neutralization of Unfractionated Heparin and Enoxaparin by Andexanet Alfa.
Lewis J; Iqbal O; Jeske W; Hoppensteadt D; Siddiqui F; Fareed J
Clin Appl Thromb Hemost; 2022; 28():10760296221099934. PubMed ID: 35535398
[TBL] [Abstract][Full Text] [Related]
11. Neutralization of the anticoagulant activity of low molecular weight heparin LU 47311 (Clivarin) in man by protamine chloride.
Andrassy K; Eschenfelder V; Weber E
Thromb Res; 1994 Jan; 73(2):85-93. PubMed ID: 8171416
[TBL] [Abstract][Full Text] [Related]
12. Reversal of heparin-induced increases in aPTT in the rat by PM102, a novel heparin antagonist.
Cushing DJ; Cooper WD; Cohen ML; McVoy JR; Sobel M; Harris RB
Eur J Pharmacol; 2010 Jun; 635(1-3):165-70. PubMed ID: 20307530
[TBL] [Abstract][Full Text] [Related]
13. Neutralization of the antithrombotic effects of heparin and Fraxiparin by protamine sulfate.
Racanelli A; Fareed J
Thromb Res; 1992 Nov; 68(3):211-22. PubMed ID: 1471069
[TBL] [Abstract][Full Text] [Related]
14. Andexanet Alfa Neutralizes the Anticoagulant Effects of Unfractionated Heparin of Bovine, Ovine and Porcine Origin Almost as Protamine Sulfate.
Siddiqui F; Hoppensteadt D; Jeske W; Ramacciotti E; Tafur A; Fareed J
Clin Appl Thromb Hemost; 2024; 30():10760296241247558. PubMed ID: 38656136
[TBL] [Abstract][Full Text] [Related]
15. Structural features and bleeding activity of commercial low molecular weight heparins: neutralization by ATP and protamine.
Dietrich CP; Shinjo SK; Moraes FA; Castro RA; Mendes A; Gouvea TC; Nader HB
Semin Thromb Hemost; 1999; 25 Suppl 3():43-50. PubMed ID: 10549715
[TBL] [Abstract][Full Text] [Related]
16. The pharmacological profile of the low molecular weight heparin 21-23 in man: anticoagulant, lipolytic and protamine reversible effects.
Harenberg J; Stehle G; Dempfle CE; von Hodenberg E; Heene DL
Folia Haematol Int Mag Klin Morphol Blutforsch; 1989; 116(6):967-80. PubMed ID: 2483715
[TBL] [Abstract][Full Text] [Related]
17. [Reversal for heparins and new anticoagulant treatments].
Kortchinsky T; Vigué B; Samama CM
Ann Fr Anesth Reanim; 2013 Jan; 32(1):37-49. PubMed ID: 23273505
[TBL] [Abstract][Full Text] [Related]
18. Comparison of antithrombotic and hemorrhagic effects of edoxaban, a novel factor Xa inhibitor, with unfractionated heparin, dalteparin, lepirudin and warfarin in rats.
Morishima Y; Honda Y; Kamisato C; Shibano T
Thromb Res; 2013 Aug; 132(2):234-9. PubMed ID: 23768448
[TBL] [Abstract][Full Text] [Related]
19. M118--a rationally engineered low-molecular-weight heparin designed specifically for the treatment of acute coronary syndromes.
Kishimoto TK; Qi YW; Long A; Capila I; Sasisekharan R; Guerrero L; Fier I; Roach J; Venkataraman G
Thromb Haemost; 2009 Nov; 102(5):900-6. PubMed ID: 19888526
[TBL] [Abstract][Full Text] [Related]
20. Protamine neutralization of the release of tissue factor pathway inhibitor activity by heparins.
Harenberg J; Siegele M; Dempfle CE; Stehle G; Heene DL
Thromb Haemost; 1993 Dec; 70(6):942-5. PubMed ID: 8165616
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]